Comparing uniQure N.V. (QURE) & Its Peers
uniQure N.V. (NASDAQ: QURE) is one of 293 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare uniQure N.V. to similar companies based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.
This table compares uniQure N.V. and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|uniQure N.V. Competitors||-5,488.05%||-450.45%||-42.07%|
Risk and Volatility
uniQure N.V. has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, uniQure N.V.’s peers have a beta of 6.63, meaning that their average share price is 563% more volatile than the S&P 500.
Earnings and Valuation
This table compares uniQure N.V. and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|uniQure N.V.||$24.62 million||-$59.26 million||-3.95|
|uniQure N.V. Competitors||$330.89 million||$94.72 million||-7.18|
uniQure N.V.’s peers have higher revenue and earnings than uniQure N.V.. uniQure N.V. is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
29.9% of uniQure N.V. shares are held by institutional investors. Comparatively, 50.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 0.7% of uniQure N.V. shares are held by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of recent ratings and recommmendations for uniQure N.V. and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|uniQure N.V. Competitors||746||3053||11559||246||2.72|
uniQure N.V. presently has a consensus price target of $13.25, indicating a potential upside of 19.48%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 30.36%. Given uniQure N.V.’s peers stronger consensus rating and higher probable upside, analysts plainly believe uniQure N.V. has less favorable growth aspects than its peers.
uniQure N.V. peers beat uniQure N.V. on 9 of the 12 factors compared.
uniQure N.V. Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships. The Company’s product candidates within the Core Program include AMT-060 for Hemophilia B, AMT-130 for Huntington’s disease and S100A1 for congestive heart failure. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.